Eli Lilly and Company (NYSE:LLY) Shares Bought by Caprock Group LLC

Caprock Group LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 455.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 59,708 shares of the company’s stock after purchasing an additional 48,968 shares during the period. Eli Lilly and Company makes up 2.2% of Caprock Group LLC’s investment portfolio, making the stock its 7th largest position. Caprock Group LLC’s holdings in Eli Lilly and Company were worth $54,059,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Independent Advisor Alliance lifted its stake in Eli Lilly and Company by 1.7% during the fourth quarter. Independent Advisor Alliance now owns 32,269 shares of the company’s stock worth $18,810,000 after purchasing an additional 544 shares in the last quarter. Apexium Financial LP lifted its holdings in Eli Lilly and Company by 1,819.1% during the 4th quarter. Apexium Financial LP now owns 11,438 shares of the company’s stock worth $6,667,000 after buying an additional 10,842 shares in the last quarter. Capital Planning LLC purchased a new position in Eli Lilly and Company in the 1st quarter valued at approximately $262,000. CHURCHILL MANAGEMENT Corp acquired a new position in shares of Eli Lilly and Company in the first quarter worth $6,916,000. Finally, M&G Plc purchased a new stake in shares of Eli Lilly and Company during the first quarter worth $8,896,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 75,510 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $860.78, for a total value of $64,997,497.80. Following the transaction, the insider now owns 97,793,810 shares in the company, valued at approximately $84,178,955,771.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders sold 737,410 shares of company stock worth $669,719,100. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 1.1 %

Shares of NYSE LLY opened at $902.71 on Friday. The business has a 50-day moving average price of $895.97 and a 200 day moving average price of $827.99. The stock has a market cap of $857.94 billion, a PE ratio of 132.95, a price-to-earnings-growth ratio of 2.91 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. Equities research analysts forecast that Eli Lilly and Company will post 16.51 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.58%. Eli Lilly and Company’s payout ratio is 76.58%.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a report on Monday, August 19th. Bank of America boosted their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and raised their target price for the company from $725.00 to $1,025.00 in a report on Monday, August 12th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Thursday. Finally, Jefferies Financial Group raised their price objective on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $961.76.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.